Joel B. Raffel - Publications

A survey of regulatory recommendations for waivers of in vivo bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2.

Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques

Published: April 03, 2025

Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm.

Journal: Annals of neurology

Published: November 07, 2019

Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.

Journal: Molecular imaging and biology

Published: February 24, 2019

Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 25, 2018

Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Journal: Drugs

Published: April 22, 2017

Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 24, 2017

Neurofilament light as an immune target for pathogenic antibodies.

Journal: Immunology

Published: February 06, 2017

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.

Journal: PLoS medicine

Published: January 10, 2017

[11 C]PBR-28 positron emission tomography in multiple sclerosis: Neuroinflammation or otherwise?

Journal: Annals of neurology

Published: November 30, 2016

Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.

Journal: PloS one

Published: July 04, 2016

Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 28, 2016

Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care.

Journal: PloS one

Published: January 19, 2016